FDA-Senate row reaches standoff over Ketek

Share this article:
The chairman of the Senate Finance Committee says the FDA’s acting commissioner is not complying fully with requests for information on the agency’s review of Sanofi-Aventis antibiotic Ketek. Sen. Charles Grassley (R-Iowa) has been investigating the FDA’s handling of Ketek, which has been linked to reports of liver failure. The agency’s acting chief, Andrew von Eschenbach, has not produced the information sought, Grassley told Health and Human Services Secretary Mike Leavitt in a letter. The letter stated that “at least three FDA officials, who played integral roles in the FDA's review of Ketek, were never asked to review their files and turn over relevant documents,” Reuters reported. Failure to comply with subpoenas sent by his committee is the reason for a hold the senator placed on von Eschenbach’s confirmation to head FDA, Grassley has said. In a written response to the senator’s questions released last week, the acting commissioner said providing the information would comprise his agency’s independence. Disclosure of information “that might relate to any open investigation in response to congressional inquiries poses an inherent threat to the integrity of the executive branch’s enforcement and litigation functions,” von Eschenbach wrote, according to the Associated Press. A senior communications official at FDA told MM&M that the agency has “worked diligently” with the senator’s staff since April to provide information. The FDA is holding an advisory panel meeting on Dec. 14 and 15 to gather input from outside experts about whether Ketek should remain on the market.
Share this article:

Email Newsletters

More in News

FDA kind of OKs Lilly/BI's Lantus look-alike

FDA kind of OKs Lilly/BI's Lantus look-alike

Sanofi's patent lawsuit triggered the tentative approval of the Lilly-BI Lantus competitor.

GSK relaunches COPD.com

GSK relaunches COPD.com

The refresh launched soon after the company encouraged investors to take a long view of GSK as the firm posted weak respiratory numbers.

Six things for pharma marketers to know: Tuesday, August 19

Six things for pharma marketers to know: Tuesday, ...

Lilly/BI receives tentative approval for insulin biosimilar; Ebola death rate hits new high; LaMattina sounds off on Pfizer's oncology efforts; art therapy becoming the norm in hospitals.